Ottawa Hospital Research Institute

In a randomized clinical trial with 797 adults, no significant differences were found between once-daily vs more frequent screening and pressure-supported vs T-piece SBTs for time to successful extubation. However, a significant interaction was identified: more frequent screening with pressure-supported SBTs increased the time to successful extubation, while once-daily screening with pressure-supported SBTs did not reduce this time compared to T-piece SBTs.

A randomized clinical trial (TACT) found that tranexamic acid (TXA) did not reduce red blood cell (RBC) transfusions in patients undergoing open radical cystectomy for bladder cancer. TXA was administered before incision and during surgery, but no significant difference in RBC transfusions was observed compared to placebo. Based on these results, routine use of TXA during open radical cystectomy is not recommended.

VITdALIZE-KIDS is a phase III, multicenter, double-blind RCT designed with CCCTG to assess vitamin D supplementation in PICU patients. The trial will recruit 766 patients from 11 Canadian centers, with randomization stratified by site. The primary outcome is HRQL at 28 ± 7 days post-intervention, measured by PedsQL™. A metabolomics sub-study will analyze blood and urine samples to understand the broader metabolic effects of vitamin D correction. Safety monitoring includes reporting adverse events and following Health Canada guidelines. The trial protocol adheres to SPIRIT guidelines and has received necessary ethical and regulatory approvals.